UCB (UCBJY) Expected to Release Earnings on Thursday

UCB (OTCMKTS:UCBJY) will likely be issuing its resultson Thursday, July 30th. Analysts expect the company to post earnings of $2.91 per share and revenue of $4.6424 billion for the quarter.

UCB Stock Performance

Shares of UCBJY opened at $139.06 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. The company has a 50-day simple moving average of $143.74 and a 200-day simple moving average of $147.84. UCB has a 52 week low of $102.90 and a 52 week high of $168.76.

Analysts Set New Price Targets

UCBJY has been the subject of several recent research reports. Zacks Research raised UCB from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Finally, Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a research report on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.